Boston Scientific has reported Q2 revenues of around $5.4bn, indicative of a 7.5% year-over-year (YoY) rise, yet has elected to trim its full-year outlook.
The lion’s share of Boston’s revenues came from its cardiovascular segment at around $3.6bn, indicative of an 8.3% YoY uplift and driven by the ongoing adoption of its FARAPULSE pulsed field ablation (PFA) system
Meanwhile, Boston’s medsurg business generated $1.8bn. Endoscopy contributed $793m, while urology and neuromodulation yielded $684m and $341m, respectively. Following the release of its Q1 financials in April, the medtech giant anticipated 2026 revenue growth between 7%-8.5% with earnings mooted to fall in the $3.34 to $3.41 per share range.
Following its Q2 results, however, Boston now expects its 2026 earnings per share (EPS) to fall between $3.28 and $3.32, with sales growth of approximately 5.5%-6.5%. The tempered 2026 outlook is likely due in part to Boston’s planned global restructuring programme that the company said is being initiated in an effort to drive “sustained cost efficiencies” and support continued growth across its business operations. The plan, which is expected to be complete by the end of 2029, was publicly disclosed in a Form 8-K filing with the US Securities and Exchange Commission (SEC) on 27 July.